{"id":84148,"date":"2024-06-05T10:57:22","date_gmt":"2024-06-05T13:57:22","guid":{"rendered":"https:\/\/megalabs.global\/eng\/?p=84148"},"modified":"2024-06-05T10:57:22","modified_gmt":"2024-06-05T13:57:22","slug":"megalabs-acquires-control-in-ds-laboratories","status":"publish","type":"post","link":"https:\/\/megalabs.global\/eng\/megalabs-acquires-control-in-ds-laboratories\/","title":{"rendered":"Megalabs Acquires Control in DS Laboratories"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″ width=”1\/4″][\/vc_column][vc_column width=”3\/4″][vc_column_text uncode_shortcode_id=”315421″]<\/p>\n

Megalabs has acquired majority interest and control of DS Laboratories (\u201cDS Labs\u201d), a leading dermatology company focused on science backed hair care across 50+ countries.\u00a0 This strategic move enhances Megalabs’ position in the global dermatology market and the US.<\/p>\n

For Megalabs, dermatology is a key focus area with a long and successful track record driven by its Medihealth line, including a wide portfolio of products, and more recently entering the minimally invasive aesthetics and fillers market with the acquisition of Croma-Pharma in Brazil and the distribution of its products in the Latam region.<\/p>\n

DS Labs\u2019 portfolio is highly relevant for the operation as it will strengthen Megalabs\u2019 position in dermatology and the US market.<\/p>\n

Fabian Rivero, MBA, Megalabs North America’s CEO, emphasized that this acquisition boosts the company’s growth and presence in the US with high-quality products, as \u201cDS Labs is known for its science backed hair care and skin care products\u201d.<\/p>\n

DS Labs will benefit from Megalabs’ distribution network and operational expertise, accelerating the development and delivery of new treatments globally.<\/p>\n

“Our mission has always been to improve patient outcomes through dermatological science,” said Fernando Tamez, Director of DS Labs. “Joining Megalabs allows us to expand our reach and impact”.<\/p>\n

Megalabs and DS Labs are united in their pursuit of innovation and growth. The collaboration will involve a strong emphasis on constructive teamwork and professionalism to ensure DS Labs\u2019 portfolio of effective dermatological treatment options is accessible to patients worldwide.<\/p>\n

DS Labs was advised by M&A advisor Raymond James, legal advisors Cowan, DeBaets, Abrahams & Sheppard LLP and Recalde Law Firm, P.A. and accounting & tax due diligence advisor Alvarez & Marsal. Megalabs was advised by Megalabs M&A team and legal advisors Greenberg Traurig.<\/p>\n

For further information please read press release<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/4″][\/vc_column][vc_column width=”3\/4″][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ uncode_shortcode_id=”140283″ link=”url:https%3A%2F%2Fmegalabs.global%2Feng%2Fwp-content%2Fuploads%2F2024%2F06%2FMegalabs_DS-Labs-Press-Realase-52824_full7068.pdf|target:_blank” icon_color_type=”uncode-palette” title=”Download Document”]DS Labs[\/vc_icon][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″ width=”1\/4″][\/vc_column][vc_column […]<\/p>\n","protected":false},"author":9,"featured_media":84153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-84148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/84148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/comments?post=84148"}],"version-history":[{"count":1,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/84148\/revisions"}],"predecessor-version":[{"id":84154,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/84148\/revisions\/84154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media\/84153"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media?parent=84148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/categories?post=84148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/tags?post=84148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}